WallStreetZenWallStreetZen

NASDAQ: RGLS
Regulus Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for RGLS

Based on 6 analysts offering 12 month price targets for Regulus Therapeutics Inc.
Min Forecast
$3.00+105.48%
Avg Forecast
$10.33+607.74%
Max Forecast
$28.00+1,817.81%

Should I buy or sell RGLS stock?

Based on 6 analysts offering ratings for Regulus Therapeutics Inc.
Buy
Strong Buy
2 analysts 33.33%
Buy
3 analysts 50%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their RGLS stock forecasts and price targets.

RGLS stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-08-14
lockedlocked$00.00+00.00%2024-08-09
lockedlocked$00.00+00.00%2024-06-25
lockedlocked$00.00+00.00%2024-05-31
lockedlocked$00.00+00.00%2024-03-18
Wells Fargo
Top 19%
82
HoldMaintains$3.00+105.48%2024-03-13

1 of 1

Forecast return on equity

Is RGLS forecast to generate an efficient return?
Company
-164.7%
Industry
-388.81%
Market
59.09%
RGLS's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is RGLS forecast to generate an efficient return on assets?
Company
-155.3%
Industry
27.33%
RGLS is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

RGLS earnings per share forecast

What is RGLS's earnings per share in the next 3 years based on estimates from 3 analysts?
Avg 1 year Forecast
-$0.80
Avg 2 year Forecast
-$1.20
Avg 3 year Forecast
-$1.60

RGLS revenue forecast

What is RGLS's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$29.9M
Avg 2 year Forecast
$157.0M
Avg 3 year Forecast
$407.8M

RGLS vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
RGLS$1.46$10.33+607.74%Buy
CTXR$0.53$5.00+843.40%Strong Buy
ORMP$2.35N/AN/A
VSTM$2.40$12.40+416.67%Strong Buy
CKPT$2.10$20.00+852.38%Buy
View Top Biotech Stocks

Regulus Therapeutics Stock Forecast FAQ

Is Regulus Therapeutics Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: RGLS) stock is to Buy RGLS stock.

Out of 6 analysts, 2 (33.33%) are recommending RGLS as a Strong Buy, 3 (50%) are recommending RGLS as a Buy, 1 (16.67%) are recommending RGLS as a Hold, 0 (0%) are recommending RGLS as a Sell, and 0 (0%) are recommending RGLS as a Strong Sell.

If you're new to stock investing, here's how to buy Regulus Therapeutics stock.

What is RGLS's earnings growth forecast for 2024-2026?

(NASDAQ: RGLS) Regulus Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.4%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.

Regulus Therapeutics's earnings in 2024 is -$35,390,000.On average, 3 Wall Street analysts forecast RGLS's earnings for 2024 to be -$52,372,701, with the lowest RGLS earnings forecast at -$54,991,336, and the highest RGLS earnings forecast at -$49,754,066. On average, 3 Wall Street analysts forecast RGLS's earnings for 2025 to be -$78,559,051, with the lowest RGLS earnings forecast at -$123,075,847, and the highest RGLS earnings forecast at -$54,336,677.

In 2026, RGLS is forecast to generate -$104,418,072 in earnings, with the lowest earnings forecast at -$152,535,491 and the highest earnings forecast at -$56,300,653.

What is RGLS's revenue growth forecast for 2028-2030?

(NASDAQ: RGLS) Regulus Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.98%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.26%.

Regulus Therapeutics's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast RGLS's revenue for 2028 to be $1,959,786,464, with the lowest RGLS revenue forecast at $1,959,786,464, and the highest RGLS revenue forecast at $1,959,786,464. On average, 1 Wall Street analysts forecast RGLS's revenue for 2029 to be $10,277,880,668, with the lowest RGLS revenue forecast at $10,277,880,668, and the highest RGLS revenue forecast at $10,277,880,668.

In 2030, RGLS is forecast to generate $26,698,489,948 in revenue, with the lowest revenue forecast at $26,698,489,948 and the highest revenue forecast at $26,698,489,948.

What is RGLS's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: RGLS) forecast ROA is -155.3%, which is lower than the forecast US Biotechnology industry average of 27.33%.

What is RGLS's Price Target?

According to 6 Wall Street analysts that have issued a 1 year RGLS price target, the average RGLS price target is $10.33, with the highest RGLS stock price forecast at $28.00 and the lowest RGLS stock price forecast at $3.00.

On average, Wall Street analysts predict that Regulus Therapeutics's share price could reach $10.33 by Aug 14, 2025. The average Regulus Therapeutics stock price prediction forecasts a potential upside of 607.74% from the current RGLS share price of $1.46.

What is RGLS's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: RGLS) Regulus Therapeutics's current Earnings Per Share (EPS) is -$1.25. On average, analysts forecast that RGLS's EPS will be -$0.80 for 2024, with the lowest EPS forecast at -$0.84, and the highest EPS forecast at -$0.76. On average, analysts forecast that RGLS's EPS will be -$1.20 for 2025, with the lowest EPS forecast at -$1.88, and the highest EPS forecast at -$0.83. In 2026, RGLS's EPS is forecast to hit -$1.60 (min: -$2.33, max: -$0.86).

What is RGLS's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: RGLS) forecast ROE is -164.7%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.